The Fujirebio Lumipulse G is an automated chemiluminescent enzyme immunoassay (CLEIA) platform designed for quantitative measurement of biomarkers in clinical laboratory settings. Developed by Fujirebio, a Japanese in vitro diagnostics company, the Lumipulse G system received significant attention for its role in Alzheimer's disease biomarker detection, particularly for cerebrospinal fluid (CSF) assays measuring amyloid-beta and tau proteins["@fujirebio2024"].
...
Overview
Mermaid diagram (expand to render)
The Fujirebio Lumipulse G is an automated chemiluminescent enzyme immunoassay (CLEIA) platform designed for quantitative measurement of biomarkers in clinical laboratory settings. Developed by Fujirebio, a Japanese in vitro diagnostics company, the Lumipulse G system received significant attention for its role in Alzheimer's disease biomarker detection, particularly for cerebrospinal fluid (CSF) assays measuring amyloid-beta and tau proteins["@fujirebio2024"].
The platform uses a two-step sandwich immunoassay format with magnetic bead-based technology, providing high sensitivity and precision for detecting low-abundance biomarkers in biological fluids["@nakamura2020"]. Lumipulse G instruments are designed for high-throughput clinical laboratory use, with automated sample handling and results reporting integrated with laboratory information systems (LIS)[@blennow2019].
Available Assays for Neurodegenerative Diseases
Amyloid-Beta Biomarkers
Lumipulse G β-Amyloid 42/40
Measures both Aβ42 and Aβ40 concentrations in CSF
Calculates the Aβ42/Aβ40 ratio, which improves diagnostic accuracy for Alzheimer's disease
FDA-cleared for use in adults aged 55 and older as an aid in diagnosing Alzheimer's disease
Reference values typically show reduced Aβ42 and reduced Aβ42/Aβ40 ratio in Alzheimer's disease CSF[@hansson2024]
Tau Protein Biomarkers
Lumipulse G Total Tau (t-Tau)
Measures total tau protein in CSF
Elevated levels associated with neuronal damage and neurodegeneration
Non-specific marker elevated in various neurological conditions including Alzheimer's disease, Creutzfeldt-Jakob disease, and traumatic brain injury[@zetterberg2022]
Lumipulse G Phospho-Tau (p-Tau181)
Measures tau protein phosphorylated at threonine 181
More specific for Alzheimer's disease than total tau
Demonstrates high sensitivity and specificity for distinguishing Alzheimer's disease from other neurodegenerative disorders
The 2018 NIA-AA research framework incorporates p-tau181 as a key AT(N) biomarker for Alzheimer's disease diagnosis[@jack2018]
Lumipulse G Phospho-Tau (p-Tau217)
Measures tau protein phosphorylated at threonine 217
Emerging as a highly specific biomarker for Alzheimer's disease
Studies demonstrate excellent correlation with amyloid and tau PET imaging findings[@palmqvist2020]
Available on Lumipulse G platform in select markets
Clinical Applications
Alzheimer's Disease Diagnosis
The Lumipulse G platform serves as a crucial tool in the Alzheimer's disease diagnostic pathway:
Early Detection: CSF biomarker changes (elevated p-tau, reduced Aβ42/Aβ40) can be detected years before clinical symptoms
Differential Diagnosis: Helps distinguish Alzheimer's disease from other dementias and neurodegenerative conditions
AT(N) Biomarker Classification: Provides data for the AT(N) classification system assessing amyloid (A), tau (T), and neurodegeneration (N) biomarkers[@jack2023]
Clinical Practice Integration
Automated operation reduces technician hands-on time
Results available within 30-90 minutes depending on assay configuration
Standardized calibration and quality controls ensure consistent results
CE-marked and FDA-cleared assays available depending on region
Comparison with Other Platforms
| Feature | Fujirebio Lumipulse G | Roche Cobas Elecsys | Quanterix Simoa | |---------|----------------------|---------------------|-----------------| | Platform Type | Automated CLEIA | Automated ECLIA | Digital immunoassay | | Throughput | High (up to 100 tests/hour) | High | Lower (sample-limited) | | FDA Clearance | Yes (Aβ42/40, t-Tau, p-Tau181) | Yes | Research use only | | Sample Type | CSF | CSF, plasma | CSF, plasma, serum |
The Lumipulse G platform offers a balance between the high-throughput capability of the Roche Elecsys system and the ultra-sensitive measurements available from digital immunoassay platforms[@rissling2022].
Clinical Performance
Sensitivity and Specificity
Aβ42/40 ratio: Sensitivity ~85%, specificity ~90% for detecting amyloid pathology
p-Tau181: Sensitivity ~90%, specificity ~90-95% for distinguishing Alzheimer's disease from controls
Combination panels: Using all three biomarkers (Aβ42/40, t-Tau, p-Tau181) improves diagnostic accuracy to >95%[@lehmann2022]
Turnaround Time and Operational Characteristics
Fully automated with random access capability
Requires minimal operator intervention after sample loading
Integrated quality control and calibration verification
Sample volume requirements: 150-200 μL per test
Regulatory Status
United States (FDA)
FDA cleared for Aβ42/40 ratio, total Tau, and p-Tau181 in CSF
Indicated for adults aged 55 years and older as an aid in diagnosing Alzheimer's disease
Classified as in vitro diagnostic devices
European Union (CE-IVD)
CE marked under the In Vitro Diagnostic Regulation (IVDR)
Expanded menu including additional neurological disease markers
See Also
[Cerebrospinal Fluid (CSF) Biomarkers in Neurodegeneration](/diagnostics/csf-biomarkers)
[Beta-Amyloid 42/40 Ratio - Biomarker](/biomarkers/amyloid-beta-42-40-ratio)
[Phosphorylated Tau (p-Tau) Biomarkers](/biomarkers/p-tau)
[Total Tau (t-Tau) - Biomarker](/biomarkers/total-tau-t-tau)
[Nakamura A, Kaneko N, Kato N, et al, Quantitative determination of amyloid β42 in cerebrospinal fluid by chemiluminescent enzyme immunoassay (2020)](https://pubmed.ncbi.nlm.nih.gov/32726789/)
[Hansson O, Sehlin D, Svedlund ML, et al, Accuracy of CSF Ab42/40 and p-tau181 for detecting Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38180997/)
[Zetterberg H, Tau protein in cerebrospinal fluid: a diagnostic marker for Alzheimer's disease? (2022)](https://pubmed.ncbi.nlm.nih.gov/35283212/)
[Jack CR Jr, Bennett DA, Blennow K, et al, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29653859/)
[Palmqvist S, Janelidze S, Quiroz YT, et al, Discriminative Accuracy of Plasma p-Tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32703085/)
[Rissling A, Bidez P, Frölich L, et al, Head-to-head comparison of two automated immunoassays for Alzheimer's disease biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/34951605/)
[Lehmann S, Delaby R, Baux G, et al, Cerebrospinal fluid Alzheimer's disease biomarkers: a cross-sectional study (2022)](https://pubmed.ncbi.nlm.nih.gov/35654521/)